All too often, economic progress and conservation of nature are seen as mutually exclusive. Indeed, biodiversity loss is considered to be the price to pay for development. In a new report, the Cambridge Institute for Sustainability Leadership (CISL), in cooperation with UBP, shows how the opposite is true by guiding financial institutions to measure their nature-related financial risks.
UBP talks to Stéphane Bancel, Moderna CEO, to learn how the mRNA technology not only made one of the first COVID-19 vaccines possible, but, more importantly for investors, has the potential to disrupt the broader pharmaceutical industry in its wake.
